Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis  plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.

Novartis to answer U.S. Senate demand for data manipulation details

An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated.

Novartis executive sold shares before drug data manipulation made public

Novartis AG  said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million.

Novartis replaces top scientists at Avexis after drug data manipulated

Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.
The post Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data appeared first on Investor's Business Daily.

Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data

Brian Kaspar and Allan Kaspar "have not been involved in any operations at AveXis since early May 2019 and are no longer with the company," Novartis said.

Novartis allegedly fires brother scientists over data manipulation

Swiss drugmaker Novartis  has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept.

Novartis names Bulto as new head of U.S. drugs business

AbbVie

Johnson & Johnson

Pfizer

And the one big pharma most likely to benefit the most.

5 Biggest New Drugs Approved in 2019 So Far

It's going to take more than a couple of embarassing revelations to stop this train.

5 Reasons Novartis Shareholders Aren't Shaken

Novartis AG (NYSE: NVS)'s Zolgensma, the first gene therapy approved for pediatric patients with spinal muscular dystrophy Type 1, has caught the FDA's attention due to a disclosure by the product's manufacturer about a data manipulation issue.

FDA Investigates Data Manipulation Issue With Newly Approved Novartis Drug Zolgensma

The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis'  more than $2 million gene therapy Zolgensma was manipulated, but the agency  believes the treatment should remain on the market.

FDA says some data testing Novartis' $2 million gene therapy was manipulated

Shares of Novartis AG NVS, -2.88% tumbled 3% Tuesday afternoon after the U.S. Food and Drug Administration said the company's AveXis unit had informed the agency of a data manipulation issue in the marketing application of pricey gene-therapy Zolgensma.

Novartis stock falls after FDA says Zolgensma BLA had a 'data manipulation issue'

The Food and Drug Administration said Tuesday that pharmaceutical company Novartis knew its application for a $2.1 million gene therapy dubbed Zolgensma contained errors.
The post Novartis Stock Dives As FDA Says Pharma Manipulated Gene Therapy Data appeared first on Investor's Business Daily.

Novartis Stock Dives As FDA Says Pharma Manipulated Gene Therapy Data

The FDA is threatening to take criminal action against Novartis, saying the drugmaker used data it knew was inaccurate in its application for a $2.1 million gene therapy.

FDA says Novartis knew its application for $2.1 million gene therapy included errors

Abbott Labs

Amgen

AstraZeneca

Eli Lilly

Merck

Roche Holding AG

Thermo Fisher Scientific

The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

10 Biggest Cancer-Fighting Stocks

Novartis  Chief Executive Vas Narasimhan pledged in an interview published on Saturday not to sell the Swiss drugmaker's generics unit Sandoz amid a revamp that has prompted speculation he is preparing to offload the business.

Novartis CEO pledges not to sell Sandoz generics unit

Novartis' BLA for crizanlizumab to treat vaso-occlusive crisis was accepted for priority review by the FDA.

Novartis' Accelerated Review Sets Up A Potential Catalyst For FDA Approval

Gilead Sciences

Gilead Sciences Inc. GILD, +0.43% has licensed three pre-clinical anti-viral programs from rival pharmaceutical giant Novartis AG NVS, +4.47% the companies announced Friday.

Gilead licensing three pre-clinical programs from Novartis

Novartis' (NVS) CEO Vas Narasimhan on Q2 2019 Results - Earnings Call Transcript

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis AG (NYSE: NVS) shares are trading higher after the company reported second-quarter EPS and sales results higher from last year.

Novartis Trades Higher On Q2 Earnings, Guidance Raise

Novartis  boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.

Novartis raises full-year targets, aims to settle U.S. lawsuit

Novartis  Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close the chapter on allegedly aggressive business practices that exposed it to litigation risks.

Novartis CEO sets aside $700 million to settle doctor bribery lawsuit

Novartis earnings topped views, while Q2 revenue was in line. The Swiss drug giant raised some 2019 guidance.

Novartis Earnings Top; Swiss Drug Giant's Sales In Line

Novartis  lifted full-year sales and profit targets on Thursday, helped by innovative medicine sales and as the Swiss drugmaker's slimmed-down Sandoz generics unit saw accelerating revenue in markets outside the United States.

Novartis raises 2019 guidance, helped by Sandoz generics unit

Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%.

News for Novartis Stock (NVS)